Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
Sign Up to like & getrecommendations! Published in 2017 at "Brain and Behavior"
DOI: 10.1002/brb3.737
Abstract: Continuous levodopa‐carbidopa intestinal gel (LCIG) diminishes daily “off” time and dyskinesia in patients with advanced Parkinson′s disease (PD). Complications are common with percutaneous endoscopic gastrostomy with a jejunal extension tube (PEG‐J). read more here.
Keywords: levodopa carbidopa; carbidopa intestinal; parkinson disease; advanced parkinson ... See more keywords
l‐Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior
Sign Up to like & getrecommendations! Published in 2017 at "Brain and Behavior"
DOI: 10.1002/brb3.848
Abstract: In Parkinson's disease (PD), effects on behavior and cognition of levodopa/carbidopa intestinal gel (LCIG) and subthalamic stimulation (STN‐DBS) and their practical consequences remain controversial. This study was designed to analyze the possible effects of these… read more here.
Keywords: intestinal gel; stimulation; carbidopa intestinal; cognition behavior ... See more keywords
Enteral Feeding Using Levodopa‐Carbidopa Intestinal Gel Percutaneous Endoscopic Gastrostomy Tube
Sign Up to like & getrecommendations! Published in 2017 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.12490
Abstract: In Parkinson’s disease (PD), dysphagia has a significant influence on nutritional status. When dysphagia is resistant to oral nutrition intervention, enteral nutrition using a percutaneous endoscopic gastrostomy (PEG) can be considered. A levodopa (L-DOPA)-carbidopa intestinal… read more here.
Keywords: endoscopic gastrostomy; percutaneous endoscopic; intestinal gel; carbidopa intestinal ... See more keywords
Levodopa‐Carbidopa Intestinal Gel in a Pediatric Parkinsonism‐plus Syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.12509
Abstract: In Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG) is indicated in control of motor fluctuations, dyskinesias1 and non-motor symptoms. We here report the first case of LCIG pediatric use. Our patient presented with upper limb tremor… read more here.
Keywords: levodopa carbidopa; gel pediatric; carbidopa intestinal; intestinal gel ... See more keywords
How Do I Manage Patients With the Levodopa/Carbidopa Intestinal Gel?
Sign Up to like & getrecommendations! Published in 2019 at "Movement Disorders Clinical Practice"
DOI: 10.1002/mdc3.12701
Abstract: The levodopa carbidopa intestinal gel is a device‐assisted therapy used for the management of fluctuating motor symptoms of Parkinson's disease that are refractory to oral therapy. The approach has demonstrable clinical value, but consideration of… read more here.
Keywords: levodopa carbidopa; manage patients; patients levodopa; carbidopa intestinal ... See more keywords
Levodopa–Carbidopa–Entacapone Intestinal Gel in Advanced Parkinson Disease: A Multicenter Real-Life Experience
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000001707
Abstract: Background: For Parkinson disease (PD) patients who have been diagnosed with advanced disease that can no longer be effectively controlled with optimized oral or transdermal medications, a range of device-aided therapies (DAT) are available, comprising… read more here.
Keywords: treatment; intestinal gel; lecig treatment; levodopa ... See more keywords
Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
Sign Up to like & getrecommendations! Published in 2024 at "European Journal of Neurology"
DOI: 10.1111/ene.16582
Abstract: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long‐term efficacy and safety data are lacking. read more here.
Keywords: entacapone carbidopa; levodopa entacapone; carbidopa intestinal; intestinal gel ... See more keywords
Levodopa‐carbidopa intestinal gel: is the naso‐jejunal phase a redundant convention?
Sign Up to like & getrecommendations! Published in 2018 at "Internal Medicine Journal"
DOI: 10.1111/imj.13754
Abstract: Levodopa‐carbidopa intestinal gel (LCIG) is an effective treatment for Parkinson disease. Initiating therapy involves an initial naso‐jejunal (NJ) titration phase. The NJ phase is prolonged with significant morbidity. The aim of this study is to… read more here.
Keywords: levodopa carbidopa; phase; carbidopa intestinal; naso jejunal ... See more keywords
Az intestinalis gél bevezetésekor rögzített jellemzők tízéves változásai előrehaladott Parkinson-kóros betegekben.
Sign Up to like & getrecommendations! Published in 2022 at "Orvosi hetilap"
DOI: 10.1556/650.2022.32534
Abstract: INTRODUCTION Parkinson's disease is a neurodegenerative disease, the symptoms of which can be treated reasonably well; however, therapeutic recommendations need to be refined based on the observations from everyday practice. OBJECTIVE We aimed to analyze… read more here.
Keywords: year; period; disease; parkinson ... See more keywords
Levodopa–Entacapone–Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson’s Disease: A Single Center Real-World Experience
Sign Up to like & getrecommendations! Published in 2024 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics16040453
Abstract: Levodopa–entacapone–carbidopa intestinal gel infusion is a relatively new treatment option for advanced Parkinson’s disease. We aimed to describe and analyze the characteristics of de novo levodopa–entacapone–carbidopa intestinal gel therapy in 20 consecutive patients with advanced… read more here.
Keywords: entacapone carbidopa; intestinal gel; carbidopa intestinal; levodopa entacapone ... See more keywords